Ownership and insider activity for Edgewise Therapeutics, Inc. (EWTX): recent transactions by executives and directors. Track how corporate insiders are trading the stock.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial.
Price
| Price | $38.87 (closing price, November 5, 2026) |
| Market Cap | $4.2B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-01 | Fox Jonathan C | A-Award | 308 | |
| 2026-08-12 | Nofi Michael | A-Award | 48,750 | $2.1M |
| 2026-08-12 | Donovan Joanne M. | A-Award | 65,000 | $2.8M |
| 2026-08-12 | Russell Alan J | A-Award | 65,000 | $2.8M |
| 2026-08-12 | MOORE JOHN R | A-Award | 65,000 | $2.8M |
| 2026-08-12 | Derakhshan Behrad | A-Award | 100,000 | $4.4M |
| 2026-08-12 | Nofi Michael | A-Award | 48,750 | |
| 2026-08-12 | Nofi Michael | A-Award | 24,375 | |
| 2026-08-12 | Donovan Joanne M. | A-Award | 65,000 | |
| 2026-08-12 | Donovan Joanne M. | A-Award | 32,500 |
Balance Sheet (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.7M | $104.9M | $15.6M | $22.0M | $86.1M | $41.7M | $61.1M |
| Short-term Investments | 0 | $24.2M | $265.2M | $330.0M | $232.3M | $428.5M | $469.0M |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $24.0M | $129.6M | $283.8M | $357.0M | $327.0M | $475.5M | $543.4M |
| Property, Plant & Equipment | $498,000 | $516,000 | $912,000 | $9.9M | $12.7M | $11.1M | $9.2M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | $24.5M | $131.1M | $285.2M | $367.1M | $340.0M | $486.8M | $552.6M |
| Accounts Payable | $667,000 | $1.6M | $3.8M | $6.1M | $4.0M | $5.6M | $6.0M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $1.1M | $4.3M | $10.5M | $16.6M | $16.8M | $23.9M | $27.4M |
| Long-term Debt | 0 | $160.2M | 0 | 0 | 0 | 0 | $3.0M |
| Total Liabilities | $41.4M | $164.6M | $10.8M | $20.4M | $21.2M | $27.6M | $30.3M |
| Retained Earnings | -$17.0M | -$34.1M | -$77.0M | -$144.6M | -$244.8M | -$378.6M | -$546.4M |
| Total Equity | -$16.9M | -$33.4M | $274.4M | $346.7M | $318.8M | $459.2M | $522.3M |
| Total Debt | 0 | $160.2M | 0 | $4.4M | $5.4M | $4.7M | $4.0M |
| Net Debt | -$23.7M | $31.1M | -$280.8M | -$347.5M | -$313.0M | -$465.4M | -$526.1M |
| Working Capital | $22.9M | $125.3M | $273.3M | $340.4M | $310.2M | $451.6M | $516.0M |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 12.30 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 49.11 |
Profitability
| Return on Equity | 130.43% |
| Return on Invested Capital | -11.55% |
| Return on Assets | 56.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: PTCT · DYN · VRTX · 0QZU.L · MRNA · REGN · 0R2M.L · ARGX
Explore sector: Healthcare · Biotechnology
More sections of EWTX: Overview · Financials · Valuation · Estimates · Technical
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks